Breckenridge Pharmaceutical, Inc. Announces Acquisition Of 5 ANDA's
Published: Oct 03, 2017
BOCA RATON, Fla., Oct. 3, 2017 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today it has acquired five (5) Abbreviated New Drug Applications from Nostrum Laboratories Inc., a wholly owned subsidiary of Nostrum Pharmaceuticals, LLC. Three of the acquired assets are FDA approved and will be sold by Breckenridge under its label. Two of the assets are filed and pending with FDA with anticipated approval dates within the next 12 months. The total generic market value for these products is $305 Million, according to July 2017 IMS data.
The three approved ANDAs are CNS products indicted for the treatment of Attention Deficit Disorders and Narcolepsy Attention Deficit Disorders in various dosage forms.
The parties have entered into a separate agreement whereby Nostrum will remain the exclusive manufacturer for certain assets.
Breckenridge Pharmaceutical, Inc. is a privately-held own-label distributor that performs pharmaceutical marketing, research and development, as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: tablets, capsules, soft gel capsules, liquids, suspensions, ophthalmics, nasal sprays, powders and injectable products. www.bpirx.com
Nostrum Laboratories, Inc. is a wholly owned subsidiary of Nostrum Pharmaceuticals, LLC principally engaged in the development, manufacture and commercialization of specialty pharmaceutical products and controlled release orally administered generic drugs utilizing its proprietary controlled release drug delivery technologies.
SOURCE Breckenridge Pharmaceutical, Inc.